Healthcare Leadership Council's "The Future is Here" Profiles inVentiv Medical Management Program Among The Breakthrough Innovations Transforming Healthcare
BURLINGTON, Mass., Nov. 21, 2013 /PRNewswire/ -- inVentiv Health, a leading global provider of best-in-class Clinical, Commercial and Consulting Services, announced today that a cutting-edge inVentiv program for managing the care of chronic kidney disease has been included in a compilation of breakthrough innovations helping transform the American healthcare system.
The Healthcare Leadership Council (HLC), a Washington, D.C.-based coalition of the nation's premier healthcare companies and organizations, compiled a directory of some of the most important healthcare innovations of the past year in "The Future is Here: Transforming American Healthcare Through Private Sector Innovation." The book included a profile of an innovative Comprehensive Kidney Care Management (CKC) program developed by inVentiv Medical Management®. Chronic kidney disease is a major driver of costs to the U.S. healthcare system.
inVentiv's CKC program was designed to meet three goals established under the Accountable Care Act for the delivery of the most appropriate care at the most appropriate price producing positive outcomes for the consumer. The CKC program focuses on early detection, lifestyle interventions, transplantation and dialysis as a last resort. Other care management programs tend to focus on late-stage disease strategies and negotiating lower prices for dialysis alone.
Led by an in-house nephrologist, and supported by specialty certified case management nurses, and certified claims analysts, the CKC team uses an integrated approach to address health risks, manage health issues, and hold down treatment costs associated with chronic kidney disease. The program is structured to allow clinical experts to respond to identified risks before they escalate and such early intervention has a positive impact on both quality of care and cost.
The program produced a 6:1 return on investment for patients with stages 3-5 chronic kidney disease, including 60% saved through delaying progression to dialysis, 18% through cost containment strategies, 15% through indirect employee costs such as absenteeism, and 5% by avoiding associated cardiovascular events.
The HLC publication, being distributed to a wide audience of lawmakers and policy makers, is available at www.hlc.org/TheFutureIsHere. HLC President Mary R. Grealy said the innovations highlighted in the publication illustrate that significant, tangible progress is being made in addressing challenges facing U.S. healthcare.
"It's so easy to focus on the problems that the improvements taking place in every health sector tend to be overlooked," she said. "The fact is, leading private sector innovators are finding ways every day to improve access to care, keep people healthy, reduce costs and elevate quality."
Among the 40 organizations with innovative programs profiled in the compendium are Aetna, Boehringer Ingelheim Pharmaceuticals, Cleveland Clinic, Johnson and Johnson, Mayo Clinic, Merck, New York Presbyterian Hospital and Novo Nordisk.
About inVentiv Medical Management
inVentiv Medical Management, an inVentiv Health company, is a leading national provider of physician-directed, nurse-supported, technology-enabled, population health management solutions to third party administrators, self-funded and fully insured plans, employer groups, Accountable Care Organizations (ACOs) and health plans. With a mission of improving healthcare quality, costs and outcomes, enabled by the fully integrated inFinite Platform inVentiv Medical Management delivers seamless clinical interventions and cost management that support consumers, providers and payers. inVentiv Medical Management is headquartered in Charlotte, North Carolina. Please visit http://www.inVentivMM.com for more information.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv's 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inVentivHealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.
Contact: inVentiv Health, Inc. +1 781 425 4624 |
SOURCE inVentiv Health, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article